MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ
0.9201
+0.0633
+7.39%
After Hours: 0.9200 -0.0001 -0.01% 18:44 02/06 EST
OPEN
0.8400
PREV CLOSE
0.8568
HIGH
0.9299
LOW
0.8400
VOLUME
123.56K
TURNOVER
--
52 WEEK HIGH
4.190
52 WEEK LOW
0.8127
MARKET CAP
9.90M
P/E (TTM)
-0.3371
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PHIO last week (0126-0130)?
Weekly Report · 5d ago
Phio Pharmaceuticals to Present at DealFlow Discovery Conference in Atlantic City
Reuters · 01/26 13:15
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
Newsfile · 01/26 13:15
Weekly Report: what happened at PHIO last week (0119-0123)?
Weekly Report · 01/26 09:58
Buy Rating on Phio Pharmaceuticals: Early PH-762 Efficacy, Clean Safety Profile, and Solid Cash Runway Support Favorable Risk–Reward
TipRanks · 01/20 16:36
Phio Reports Positive Phase 1b PH-762 Skin Cancer Data
TipRanks · 01/20 14:58
Phio Pharmaceuticals Data From Phase 1b Dose Escalation Clinical Study Shows 14 Participants To Be Pathologic Responders, Including 10 With 100% Clearance
Benzinga · 01/20 14:35
PHIO PHARMACEUTICALS CORP - ANNOUNCES KEY TUMOR RESPONSE DATA FROM PH-762 TRIAL - SEC FILING
Reuters · 01/20 14:33
More
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Webull offers Phio Pharmaceuticals Corp stock information, including NASDAQ: PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.